Envue Medical risks Nasdaq delisting after shares trade below $1 for 30 sessions

PUBT · 1d ago
Envue Medical risks Nasdaq delisting after shares trade below $1 for 30 sessions
  • Envue Medical received a Nasdaq staff determination letter on July 10, 2026 for failing the $1 minimum bid price rule.
  • Shares traded below $1 for 30 straight business days from May 26, 2026 through July 8, 2026.
  • Nasdaq denied the usual 180-day cure period due to a 1-for-10 reverse split on Aug. 12, 2025.
  • The company will request a Nasdaq hearings panel review, which stays any delisting action pending a decision.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envue Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-032830), on July 10, 2026, and is solely responsible for the information contained therein.